New strategies for dealing with staphylococcus aureus colonization and the emerging methicillin-resistant staphylococcus aureus epidemic in atopic dermatitis

Chemical Immunology and Allergy

Volumn 96, Issue , 2012, Pages 113-119

  Boguniewicz, Mark ^a  

^a Children's Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BETAMETHASONE; BETAMETHASONE VALERATE; CLOBETASOL; GENTAMICIN; NEOMYCIN; PANTON VALENTINE LEUKOCIDIN; POLYPEPTIDE ANTIBIOTIC AGENT; PREDNICARBATE; STAPHYLOCOCCUS VACCINE; CALCINEURIN INHIBITOR; CLUMPING FACTOR; CORTICOSTEROID; CYTOLYSIN; DAPTOMYCIN; ENTEROTOXIN; FIBRONECTIN BINDING PROTEIN; IMMUNOGLOBULIN; LINEZOLID; LIPOTEICHOIC ACID; PEPTIDOGLYCAN; POLYSACCHARIDE; PROTEIN A; PSEUDOMONIC ACID; RECOMBINANT ANTIGEN; SUPERANTIGEN; TEICHOIC ACID; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC THERAPY; ARTICLE; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; COMMUNITY ACQUIRED PNEUMONIA; EPIDEMIC; HUMAN; HYDRATION; IMMUNE RESPONSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SKIN AND SOFT TISSUE INFECTION; SKIN CARE; SKIN FUNCTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE ACTIVATION; TISSUE REPAIR; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL THERAPY; BACTERIAL MEMBRANE; BACTERIAL SKIN DISEASE; COMMUNITY ACQUIRED INFECTION; PENICILLIN RESISTANCE; TOXIC SHOCK SYNDROME;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL TOXINS; DERMATITIS, ATOPIC; DISEASE OUTBREAKS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84859195830     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000331910     Document Type: Article

References (30)

1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group: Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124:1251-8.e23.
2. Boguniewicz M, Leung DY: Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 2010;125:4-13.
3. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-47.
4. Boucher HW, Corey GR: Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46:S344-S349.
5. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core Surveillance (ABCs) MRSA Investigators: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-1771.
6. Stryjewski ME, Chambers HF: Skin and soft tissue infections caused by community acquired methicillin resistant Staphylococcus aureus. Clin Infect Dis 2008;46:S368-S377.
7. Chambers HF: Community-associated MRSA-resistance and virulence converge. N Engl J Med 2005;352:1485-1487.
8. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B: Necrotizing fasciitis caused by communityassociated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445-1453.
9. Otto M: Community-associated MRSA: A dangerous epidemic. Future Microbiol 2007;2:457-459.
10. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J: Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg Infect Dis 2003;9:978-984.
11. Voyich JM, et al: Is Panton-Valentine leukocidin the major virulence determinant in communityassociated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006;194:1761-1770.
12. Wang R, Braughton KR, Kretschmer D, et al: Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007;13:1510-1514.
13. Schlievert PM, Strandberg KL, Lin YC, Peterson ML, Leung DY: Secreted virulence factor comparison between methicillin-resistant and methicillinsensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J Allergy Clin Immunol 2010;125: 39-49.
14. Cho SH, Strickland I, Boguniewicz M, Leung DY: Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 2001;108:269-274.
15. Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P: Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994;131: 536-540.
16. Remitz A, Kyllonen H, Granlund H, Reitamo S: Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001;107:196-197.
17. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, and Participants in the CDC-Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at http://www.cdc.gov/ncidod/dhqp/ar-mrsa-ca.html. Accessed December 12, 2011.
18. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY: Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001;108:651-652.
19. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC: Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008;3:CD003871.
20. Wollenberg A, Schnopp C: Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin N Am 2010;3:351-368.
21. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS: Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009;123:e808-e814.
22. Boguniewicz M, Nicol NH, Kelsay K, Leung DYM: A multidisciplinary approach to evaluation and treatment of atopic dermatitis. Semin Cut Med Surg 2008;27:115-127.
23. Savage PB, Li C, Taotafa U, Ding B, Guan Q: Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002;217:1-7.
24. Ding B, Taotofa U, Orsak T, Chadwell M, Savage PB: Synthesis and characterization of peptide-cationic steroid antibiotic conjugates. Org Lett 2004;6:3433-3436.
25. Chin JN, et al: Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51: 1268-1273.
26. Otto M: Targeted immunotherapy for staphylococcal infections: Focus on anti-MSCRAMM antibodies. BioDrugs 2008;22:27-36.
27. Stranger-Jones YK, Bae T, Schneewind O: Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006;103:16942-16947.
28. Glowalla E, Tosetti B, Kronke M, Krut O: Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect Immun 2009;77:2719-2729.
29. Buonpane RA, Churchill HRO, Moza B, Sundberg EJ, Peterson ML, Schlievert PM, et al: Neutralization of staphylococcal enterotoxin B by soluble, highaffinity receptor antagonists. Nat Med 2007;13: 725-729.
30. Yang X, Buonpane RA, Moza B, Nur-ur Rahman AKM, Wang N, Schlievert PM, et al: Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats. J Invest Dermatol 2008;198: 344-348.